Excitement about the potential of artificial intelligence (AI) to transform drug discovery has been building for several years. Millions of dollars have been poured into AI-based drug discovery start-ups in the US, Europe and beyond, who are all racing to reach the first true proof-of-concept for the approach.
Big pharma has also been investing in the field, both internally and in partnership with new AI-focused platforms. There is...








